| Deep Learning for Drug Design: an Artificial Intelligence Paradigm for Drug Discovery in the Big Data Era |
34 |
| Preservation and Storage Stability of Extracellular Vesicles for Therapeutic Applications |
32 |
| Therapeutic Potential of Engineered Extracellular Vesicles |
25 |
| Plharmacogenomic Biomarkers for Improved Drug Therapy- Recent Progress and Future Developments |
20 |
| Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules |
17 |
| Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells |
17 |
| A Non-invasive Liquid Biopsy Screening of Urine-Derived Exosomes for miRNAs as Biomarkers in Endometrial Cancer Patients |
16 |
| Pediatric Dose Selection and Utility of PBPK in Determining Dose |
15 |
| Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Linka Workshop Summary Report |
15 |
| Additive Manufacturing with 3D Printing: Progress from Bench to Bedside |
14 |
| Interfacial Stress in the Development of Biologics: Fundamental Understanding, Current Practice, and Future Perspective |
14 |
| Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics |
11 |
| The Na+/Cl--Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB(+)): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis |
11 |
| A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer |
10 |
| ABCB an ABC Transporter Impacting Drug Response and Disease |
10 |
| Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report |
10 |
| Individualized Dosing of Therapeutic Monoclonal Antibodiesa Changing Treatment Paradigm? |
10 |
| Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices |
10 |
| A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART((R)) |
10 |
| First-Principles and Empirical Approaches to Predicting In Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing |
9 |
| Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications |
9 |
| Effectiveness of a Cocaine Hydrolase for Cocaine Toxicity Treatment in Male and Female Rats |
8 |
| Fucoxanthin Elicits Epigenetic Modifications, Nrf2 Activation and Blocking Transformation in Mouse Skin JB6 P+ Cells |
8 |
| Optimized Renal Transporter Quantification by Using Aquaporin 1 and Aquaporin 2 as Anatomical Markers: Application in Characterizing the Ontogeny of Renal Transporters and Its Correlation with Hepatic Transporters in Paired Human Samples |
8 |
| In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-beta-Cyclodextrin Conjugate |
8 |
| Rational Selection, Criticality Assessment, and Tiering of Quality Attributes and Test Methods for Analytical Similarity Evaluation of Biosimilars |
8 |
| The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration |
8 |
| Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations |
8 |
| Dissolution and Translational Modeling Strategies Enabling Patient-Centric Drug Product Development: the M-CERSI Workshop Summary Report |
8 |
| Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model |
8 |
| Improved Prediction of Blood-Brain Barrier Permeability Through Machine Learning with Combined Use of Molecular Property-Based Descriptors and Fingerprints |
7 |
| The Phenotypic Effects of Exosomes Secreted from Distinct Cellular Sources: a Comparative Study Based on miRNA Composition |
7 |
| Development of a New Inhaler for High-Efficiency Dispersion of Spray-Dried Powders Using Computational Fluid Dynamics (CFD) Modeling |
7 |
| Recent Advances in Exosomal Protein Detection Via Liquid Biopsy Biosensors for Cancer Screening, Diagnosis, and Prognosis |
7 |
| Moringa Isothiocyanate Activates Nrf2: Potential Role in Diabetic Nephropathy |
7 |
| What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing |
7 |
| Fit-for-Purpose Quality Control System in Continuous Bioanalysis During Long-Term Pediatric Studies |
7 |
| Biodegradable Thermosensitive PLGA-PEG-PLGA Polymer for Non-irritating and Sustained Ophthalmic Drug Delivery |
6 |
| Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction |
6 |
| Screening of Drug-Transporter Interactions in a 3D Microfluidic Renal Proximal Tubule on a Chip |
6 |
| How Transporters Have Changed Basic Pharmacokinetic Understanding |
6 |
| Calibration Curves in Quantitative Ligand Binding Assays: Recommendations and Best Practices for Preparation, Design, and Editing of Calibration Curves |
6 |
| In Vitro-In Vivo Dose Response of Ursolic Acid, Sulforaphane, PEITC, and Curcumin in Cancer Prevention |
6 |
| In Vitro and In Vivo Efficacy of the Monocarboxylate Transporter 1 Inhibitor AR-C155858 in the Murine 4T1 Breast Cancer Tumor Model |
6 |
| Compensated Hydroxyl Radical Protein Footprinting Measures Buffer and Excipient Effects on Conformation and Aggregation in an Adalimumab Biosimilar |
6 |
| A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim |
6 |
| Incurred Sample Reanalysis: Time to Change the Sample Size Calculation? |
6 |
| A Simple Approach to Determine a Curve Fitting Model with a Correct Weighting Function for Calibration Curves in Quantitative Ligand Binding Assays |
6 |
| Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information |
6 |
| Investigation of the Mechanism of Therapeutic Protein-Drug Interaction Between Methotrexate and Golimumab, an Anti-TNF alpha Monoclonal Antibody |
6 |
